ProSci

CD19 Antibody [C19/366]

Product Code:
 
PSI-33-282
Product Group:
 
Primary Antibodies
Supplier:
 
ProSci
Host Type:
 
Mouse
Antibody Isotype:
 
IgG1, kappa
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
C19/366
Regulatory Status:
 
RUO
Target Species:
 
Human
Application:
 
Immunofluorescence (IF)
Shipping:
 
blue ice
Storage:
 
Aliquot and Store at -20C. Avoid freez-thaw cycles.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
PSI-33-282-100ug100ug£765.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • Show All

Further Information

Additional Names:
B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12, CD19, CD19
Application Note:
Flow Cytometry: 0.5-1 ug/million cells

Immunofluorescence: 0.5-1 ug/ml





Variations in protocols, secondaries and substrates may require the CD19 antibody to be titered up or down for optimal performance.
Background:
CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.
Buffer:
PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration:
0.2 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
Human CD19 recombinant protein was used as immunogen for this CD19 antibody.
NCBI Gene ID #:
930
NCBI Official Name:
CD19 molecule
NCBI Official Symbol:
CD19
NCBI Organism:
Homo sapiens
Physical State:
Liquid
Purification:
Protein G affinity chromatography
Research Area:
Cancer,Immunology,Signal Transduction
Swissprot #:
P15391
User NOte:
Optimal dilutions for each application to be determined by the researcher